Start
•
Completion

A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms

RecruitingRegisteredCTG

This is a Phase II, multi-centre, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 (25, 50, 100 or 200 μg LSD freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Details

Multi-centre, randomised, quadruple-blind, parallel-group Phase II trial in approximately 198 participants with DSM-5 GAD and HAM-A ≥20 comparing placebo and four ascending single doses of MM-120 (25–200 µg, oral capsule).

Primary aim is treatment of anxiety symptoms; participants on contraindicated medications will undergo tapering prior to baseline. Safety and tolerability, and standard anxiety outcome measures (including HAM-A) will be assessed.

Topics:Anxiety Disorders

Registry

Registry linkNCT05407064